Guest guest Posted October 29, 2007 Report Share Posted October 29, 2007 WASHINGTON - A second-line drug to treat a life-threatening form of leukemia has won federal approval, the Food and Drug Administration said Monday. Tasigna, known generically as nilotinib, won approval to treat chronic and accelerated phase Philadelphia chromosome-positive, chronic myeloid leukemia. The form of the blood cancer affects about 4,500 Americans a year. FDA approval is specifically for use in patients who are resistant or intolerant to previous treatment, including with another drug called Gleevec also made by the Swiss pharmaceutical company Novartis AG. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.